INZY

Inozyme Pharma
INZY

Overview Fund Activity
Delisted

INZY was delisted on the 30th of June, 2025.

Back to rankings

52 hedge funds and large institutions have $203M invested in Inozyme Pharma in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 18 increasing their positions, 14 reducing their positions, and 4 closing their positions.

Holders
52
Holders Change
+2
Holders Change %
+4%
% of All Funds
0.91%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
6
Increased
18
Reduced
14
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
SCM
1
Suvretta Capital Management
New York
$11.4M
2
MB
2
MPM BioImpact
Massachusetts
$3.72M
3
JPMorgan Chase & Co
3
JPMorgan Chase & Co
New York
$3.85M
4
Vanguard Group
4
Vanguard Group
Pennsylvania
$7.08M
5
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$17M

Top Sellers

1
RCM
1
RA Capital Management
Massachusetts
$0
2
NHAS
2
Novo Holdings A/S
Denmark
$0
3
Wellington Management Group
3
Wellington Management Group
Massachusetts
$4.23M
4
Citadel Advisors
4
Citadel Advisors
Florida
$1.1M
5
Millennium Management
5
Millennium Management
New York
$128K
Name Market Value Shares Shares
Change 		Shares
Change %
Daiwa Securities Group
51
Daiwa Securities Group
Japan
$1K 44 – –
Nisa Investment Advisors
52
Nisa Investment Advisors
Missouri
$2 200 – –
RCM
53
RA Capital Management
Massachusetts
– – -2,003,653 Closed
NHAS
54
Novo Holdings A/S
Denmark
– – -1,867,706 Closed
BCM
55
Burrage Capital Management
Massachusetts
– – -242,517 Closed
UBS Group
56
UBS Group
Switzerland
– – -48 Closed
CFGS
57
Concourse Financial Group Securities
Alabama
– – – –
1 2
3